BPC May 18 update

Moderna MRNA shares rally on release of promising initial COVID-19 vaccine data +20%

Price and Volume Movers

Moderna, Inc., (Nasdaq: MRNA) shares rallied to close up 20% to $80.00 following the release of initial data from its Phase 1 trial of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2). All eight initial participants across the 25 µg and 100 µg dose cohorts showed neutralizing antibodies at levels seen in blood samples from people who have recovered from COVID-19. A Phase 2 study is expected to begin shortly, with a Phase 3 trial to commence in July.

Novavax, Inc. (NASDAQ: NVAX) shares also rallied in response to the move made by Moderna. The company is also developing a vaccine for COVID-19 with initial data from its Phase 1 trial due in July. Shares closed up 30% to $56.96.

Neurotrope, Inc. (NASDAQ:NTRP) announced a reverse merger with Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company, resulting in a newly formed holding company to be renamed Petros Pharmaceuticals, Inc. Existing Neurotrope shareholders will own approximately 20% and Metuchen shareholders will own approximately 80% of the combined company. Shares closed down 17% to $1.19.

Arbutus Biopharma Corporation (NASDAQ: ABUS) shares are trading up 44% to $2.70 after hours following the release of follow-up data from its Phase 1a/b trial of AB-729 in patients with chronic hepatitis B virus (HBV).


A number of companies announced public offerings of their common stock. Details below:

Gamida Cell Ltd. (NASDAQ:GMDA): $5.90; -7% (-13% after hours) – stock offering.

Moderna, Inc. (NASDAQ:MRNA): $80.00; +20% (-3% after hours) - $1.25b stock offering.

Gossamer Bio, Inc. (NASDAQ:GOSS): $15.02; +6% (-11% after hours) – Stock and convertible note offering.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH): $16.16; -4% (-15% after hours) – stock offering.

Clovis Oncology, Inc. (NASDAQ:CLVS): $8.96; -8% (-7% after hours) - $85m stock offering.

bluebird bio, Inc. (NASDAQ:BLUE): $57.14; +1% - $400m stock offering.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN): $1.11; -18% - $12m direct offering.

Turning Point Therapeutics, Inc. (NASDAQ:TPTX): $63.90; flat - $250m offering.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:


Annovis Bio, Inc. (ANVS): $4.82; +35%.

Tocagen Inc. (TOCA): $1.57; +33%.

Vir Biotechnology, Inc. (VIR): $40.10; +32%.

Oncolytics Biotech Inc. (ONCY): $2.66; +30%.

IMV Inc. (IMV): $2.95; +28%.


Lyra Therapeutics, Inc. (LYRA): $12.88; -12%.

Constellation Pharmaceuticals, Inc. (CNST): $39.01; -11%.

MyoKardia, Inc. (MYOK): $110.11; -10%.

Capricor Therapeutics, Inc. (CAPR): $5.52; -8%.

Mirum Pharmaceuticals, Inc. (MIRM): $15.94; -7%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ABUS – Arbutus Biopharma Corporation
Hepatitis B (HBV)

Phase 1 Phase 1a/b multiple dose cohort data expected in 2H 2020
$149.6 million

ADMP – Adamis Pharmaceuticals Corporation
ZIMHI (naloxone HCI Injection)
Opioid overdose

NDA Filing CRL announced November 25, 2019. NDA resubmission announced May 18, 2020.
$36.4 million

CCXI – ChemoCentryx Inc.
Focal Segmental Glomerulosclerosis

Phase 2 Phase 2 trial did not meet primary endpoint - May 18, 2020.
$3.9 billion

GSK – GlaxoSmithKline PLC
Cabotegravir HPTN 083

Phase 3 Phase 3 trial stopped early due to sufficient efficacy.
$105.2 billion

HRTX – Heron Therapeutics Inc.
Postoperative Pain

Phase 1/2 Phase 1b/2 trial initiation announced May 18, 2020.
$1.7 billion

MCRB – Seres Therapeutics Inc.
Recurrent C. Difficile infection

Phase 3 Phase 3 data due mid-2020.
$398.6 million

MRNA – Moderna Inc.
Coronavirus COVID-19 vaccine

Phase 2a Phase 2a dosing has commenced - noted May 29, 2020. Phase 3 trial to start July 2020.
$22.8 billion

MYOV – Myovant Sciences Ltd.
Menstrual bleeding associated with uterine fibroids

NDA Filing NDA filing due May 2020.
$1.1 billion

MYOV – Myovant Sciences Ltd.
Relugolix - SPIRIT 1
Endometriosis-associated pain

Phase 3 Phase 3 data 2Q 2020.
$1.1 billion

RHHBY – Roche Holding Ltd ADR (Sponsored)
Tecentriq - IMpower110
Non-small cell lung cancer (NSCLC)

Approved FDA Approval announced May 18, 2020.
$296.8 billion

VTGN – VistaGen Therapeutics Inc.

Phase 2a Phase 2a trial planned.
$22.1 million